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1respite the d.ynamis character of the pharnaceutical  iudustry
and the inoreasing consumption of  1ts prod.ucts, intra-Comr'runity
trad.e in  ilris  sector has rernained. at  a relatl-rely  1ow level  d.uring
the first  years of  the Common llarket.
In  order to proteot public health,  the authorities  in  all  the
Member States have issued nurierous segulations on pharnaceuti-ca1
prcducts,  They differ  orl many pcints fron country to  count::7,
and. this  has tend-ed to isolate  r-narkets and linit  the free mo'zernent
of  such products,  Iisparities  betv'een lavre in  the var.i-ous corin';ries,
owing to  the influence 'bhey exercise on production and aistrikul;iotr
coste, cau3o clistortion  of competition  between nanufactr.rrers  in
tLre Comrrlrnity 
"
Hence the importanqe of  the d.irective on branded. pharmaceutj-caLs
now ad"opted by the Council of L{inistersr  It  is  a first  s'lep in  the
prog""s"ive alignnent of  la,vs ori pharnaceutlcals 1n the six
mea'ber countries.  The objeot is  tr'  stimulate this  .nraneh of  tradet
placing producers on equ:.1 terms as regards conpetition while
protecting public  health.
This directive  requires the ll[er:nber States to lncorporate in
their  legislation,  withj-n eighteen roonths from notific:ution  of  the
direetive,  a number of rules which can be summarized as followsr
1,  No brand,ed pharmaceutical  can be offered for  sale without
e. licence;
2.  The issue of  licences will  be subject to a number of formal-
itles  and conditionsS
(f)  Formalities:  an appllcation  s.cGonpanied' by certain
particulars  and. d.ocuments must be submitted';
(.-i )  Conditions :
(")  if  the
normal
the authoritlee nust refuse tp issue a lisence
pharnaceutisal appears to be harmful under
oonditions of use;
(b) if  it  does not have the therapeutic potency clained'
fcr  it  or if  such potency is  not ad.equately
substantia'bed by the aPPlicant;
I
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(")  if  the nr.ture and quantity of its  ingredients
are not in  conformity "rith those stated'
The ficensing proced'ure may not exceed' 120 d'ays from
the date of applicationr  seve in  exceptional caseg
The licence can be suspend-ed or r'rithd'rawn if ,  subsequentlyt
it  is  found that  the brand"ed pharmaceutical  is  harmfult
l;";-il  ;;"*  not have the therapeutic poteney claimed for. it
or that  the nature and quantity of its  ingred.iente are not
in  confornity lvith those stated '
Itisofparticulari-nteresttonotethattheCouncilof
Ministers has been abl-e to reach agreement on the question of
fr.u""p*"tic  potency, which had- eaused. d.ifficulties  and' given
rlse  io  lengttry d.iscussions among the experts '
The direotive  also conta'ins detailed rules on labelling'
This is  to  ensure that  branded pharmaceuticals  offered' for  sale
in  any llll0 country bear'the same particulars  consid'ered
"=senlial 
from thl  point  of view of public  health.
Alighnment in  this  matter is  undoubted.ly of, considerable
interest  to both prod-ucers and consumers '
This directive  ivill  be fcll-owed. by other measurps; . indeed'
a proposal for  a second directive,  which to a certain  extent
suppt-ements the first  one, has alread.y been subknitted. to  the
Council of Ministers.
It  d-eafs v,rith the supporting documents, concerning testst
which must accompany the application  for  a licenc€r  the
manufacturers  t  c,if i'gations in  resp ect of testing  their  products t
and the inspections of concritions of production and sale to be
earied  out by the natio4al authorities  '
F\rrther proposals are ln prepara'tion'  One on the use of
eolruringmattersindrugsandanotherconcerningadvertising
have reached an ad'vanced stage'
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